STEMSYNERGY THERAPEUTICS, INC.

Basic Information

1951 NW 7TH AVE
MIAMI, FL, 33136-1104

Company Profile

n/a

Additional Details

Field Value
DUNS: 826941754
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 3


  1. Development of a WNT Inhibitor for Advanced Stage Lung Cancer

    Amount: $1,499,974.00

    DESCRIPTION provided by applicant Non small cell lung cancer NSCLC is the most common lung cancer Half of NSCLC shows WNT activation marking poor survival StemSynergy Therapeutics Inc SSTI h ...

    SBIR Phase II 2014 Department of Health and Human Services National Institutes of Health
  2. Development of Wnt Pathway Inhibitors for Colorectal Cancer

    Amount: $1,999,997.00

    DESCRIPTION (provided by applicant): StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target pathways fun ...

    SBIR Phase II 2012 Department of Health and Human Services
  3. Targeting stem cell populations in lung cancer by modulating the Wnt and p53 path

    Amount: $259,451.00

    DESCRIPTION (provided by applicant): Despite significant advancements in modern medicine with regards to surgery, radiation therapy and imaging of tumors, the survival rate for patients with non-small ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Development of Wnt Pathway Inhibitors for Colorectal Cancer

    Amount: $140,000.00

    DESCRIPTION (provided by applicant): StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target pathways fund ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government